Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

Core Insights - Immuneering Corporation reported an extraordinary 86% overall survival rate at 9 months for first-line pancreatic cancer patients treated with atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) [1][3] - The company raised a total of $225 million in financing, which includes a $25 million private placement with Sanofi, extending its cash runway into 2029 [1][2][3] - Immuneering received a U.S. composition of matter patent for atebimetinib, expected to provide exclusivity until 2042 [1][5] Clinical Developments - The Phase 2a trial of atebimetinib + mGnP showed a favorable tolerability profile with only two Grade 3 adverse events (neutropenia and anemia) observed in over 10% of patients [3] - New case studies highlighted patients achieving significant responses, including one with a complete response and another who could proceed to radiation and surgery with curative intent [4][5] - Immuneering plans to report updated survival data in the first half of 2026 and begin dosing patients in a pivotal Phase 3 trial by mid-2026 [6][8] Financial Performance - As of September 30, 2025, the company reported cash and cash equivalents of $227.6 million, a significant increase from $36.1 million at the end of 2024 [8] - Research and development expenses for Q3 2025 were $10.9 million, slightly down from $11.3 million in Q3 2024, while general and administrative expenses increased to $4.5 million from $4.0 million [9][10] - The net loss for Q3 2025 was $15.0 million, or $0.38 per share, compared to a net loss of $14.6 million, or $0.49 per share, in Q3 2024 [11][20] Future Milestones - Near-term milestones include receiving regulatory feedback and preparing to begin dosing patients in the pivotal trial of atebimetinib + mGnP [6] - The company anticipates reporting updated circulating tumor DNA data at a major scientific meeting in Q2 2026 [6] - Immuneering is also planning to dose the first patient in a trial of atebimetinib in combination with Libtayo for non-small cell lung cancer in the second half of 2026 [7]